Epilepsy Epidiolex denied as non-formulary by Cigna?

Cigna's specific coverage criteria for epilepsy epidiolex are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Epidiolex as Non-Formulary — and Your Appeal Path

Epidiolex (cannabidiol) is an FDA-approved prescription medication for certain rare epilepsy syndromes. A non-formulary denial means Cigna's drug formulary either does not include Epidiolex at a covered tier, or lists it with restrictions that were not met at the time of dispensing. Non-formulary denials are not final — Cigna plans are required to offer a formulary exception process, and epilepsy patients on Epidiolex have a strong basis for exception given the absence of therapeutically equivalent formulary alternatives.

## Why This Denial Is Appealable

Formulary exceptions must be granted when there is no clinically appropriate formulary alternative for the patient's condition. For rare epilepsy syndromes such as those for which Epidiolex is specifically FDA-approved, there is typically no other approved agent with the same mechanism or indication. Cigna's own exception policy should permit coverage when a formulary drug would be less effective or would cause adverse effects, or when no formulary drug treats the condition. Documenting this clinical distinction is the core of your appeal.

## Your Federal Appeal Rights

• Internal appeal / formulary exception: Under ACA §2719 and plan terms, you are entitled to file a formulary exception request supported by a prescriber's statement. This is separate from — and can be pursued alongside — a standard internal appeal.
• External review: If the exception and internal appeal are both denied, you have approximately four months from the final adverse decision to request independent external review.
• Expedited process: Uncontrolled seizures are a serious health risk. Request expedited exception and appeal review; Cigna must respond within 72 hours for urgent cases.

## Documentation to Gather

1. Formulary alternative comparison: Obtain Cigna's current formulary and identify any drugs listed for the same condition. Your neurologist's letter should explain why each listed alternative is clinically inappropriate, less effective, or not FDA-approved for the specific syndrome. 2. Diagnosis confirmation: Specialist notes, EEG findings, and genetic testing confirming the covered epilepsy diagnosis. 3. Treatment history: Documentation of prior anti-seizure medications tried, with dates and outcomes, supporting the conclusion that Epidiolex represents a necessary step in the treatment pathway. 4. Prescriber formulary exception letter: A letter from the treating neurologist or epileptologist that (a) identifies the specific clinical reason Epidiolex is required, (b) explains why formulary alternatives are not appropriate, and (c) requests a formulary exception on medical grounds. 5. FDA label for reference: Attach the FDA prescribing information to substantiate that Epidiolex is the only agent approved for the specific indication.

## Criteria-Mapping Structure

Review Cigna's formulary exception criteria (available in the plan's Exception and Appeals documentation):

| Exception Criterion | Supporting Evidence | |---|---| | No formulary drug treats the condition | [FDA label showing unique indication] | | Formulary alternatives are contraindicated or less effective | [Neurologist letter addressing each alternative] | | Diagnosis confirmed by treating specialist | [Specialist note + EEG/genetic documentation] | | Prescriber attestation | [Medical-necessity and exception letter] |